Thursday, Oct. 22, 2009
Just in case: Items suggesting the direction of things
By ROSS MACKENZIE .
...
- According to the executive director of the Sarcoma Foundation, the federal Food and Drug Administration has "turned its back on 25 years of regulatory precedent and rejected a new cancer drug that by all known standards had passed muster for approval." Rejection of the chemotherapy drug, Yondelis, thus denies women a potentially powerful new option for fighting ovarian cancer.
...
ZAI LIMITED Y AMGEN HAN COMUNICADO HOY UN ACUERDO DE COLABORACIÓN GLOBAL DE I+D PARA EVALUAR LA COMBINACIÓN ENTRE EL ANTICUERPO CONJUGADO ZOCILURTAUG PELITECAN EN COMBINACIÓN CON TARLATAMAB ( TERAPIA BITE ) PARA EL TRATAMIENTO SMALL CELL LUNG CANCER EXTENSIVE-STAGE .///. NUEVA ESPERANZA PARA LOS PACIENTES Y POSIBLE NUEVO TRATAMIENTO ESTÁNDAR TERAPÉUTICO SMALL CELL LUNG CANCER EXTENSIVE-STAGE .
22 octubre 2009
Suscribirse a:
Comentarios (Atom)